Evidence map›Paper›PMID 21928835›Full record

ArticleBiochemistry2011

Structural insights into the activation and inhibition of histo-aspartic protease from Plasmodium falciparum.

Prasenjit Bhaumik, Huogen Xiao, Koushi Hidaka, Alla Gustchina, Yoshiaki Kiso, Rickey Y Yada, Alexander Wlodawer

Abstract read
In one paragraph

Article in Biochemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Unlocking the Enigmas ofCurrent pharmaceutical design · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Crystal structure of Plasmodium falciparum proplasmepsin IV: the plasticity of proplasmepsins.Acta crystallographica. Section F, Structural biology communications · 2016
    Article
  11. Structures of plasmepsin II from Plasmodium falciparum in complex with two hydroxyethylamine-based inhibitors.Acta crystallographica. Section F, Structural biology communications · 2015
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Prasenjit BhaumikProtein Structure Section, Macromolecular Crystallography Laboratory, National Cancer Institute, Frederick, Maryland 21702, USA.
Huogen Xiao
Koushi Hidaka
Alla Gustchina
Yoshiaki Kiso
Rickey Y Yada
Alexander Wlodawer
Frederick National Laboratory for Cancer Research · USUniversity of Guelph · CAKyoto Pharmaceutical University · JPNagahama Institute of Bio-Science and Technology · JPNational Cancer Institute · US

Funding

Protein StructureZIABC010348 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WLODAWER, ALEXANDER · 2009 to 2025
$27.5M
Intramural NIH HHS ZIA BC010348
6 · The paper itself

Abstract

Histo-aspartic protease (HAP) from Plasmodium falciparum is a promising target for the development of novel antimalarial drugs. The sequence of HAP is highly similar to those of pepsin-like aspartic proteases, but one of the two catalytic aspartates, Asp32, is replaced with histidine. Crystal structures of the truncated zymogen of HAP and of the complex of the mature enzyme with inhibitor KNI-10395 have been determined at 2.1 and 2.5 Å resolution, respectively. As in other proplasmepsins, the propeptide of the zymogen interacts with the C-terminal domain of the enzyme, forcing the N- and C-terminal domains apart, thereby separating His32 and Asp215 and preventing formation of the mature active site. In the inhibitor complex, the enzyme forms a tight domain-swapped dimer, not previously seen in any aspartic proteases. The inhibitor is found in an unprecedented conformation resembling the letter U, stabilized by two intramolecular hydrogen bonds. Surprisingly, the location and conformation of the inhibitor are similar to those of the fragment of helix 2 comprising residues 34p-38p in the prosegments of the zymogens of gastric aspartic proteases; a corresponding helix assumes a vastly different orientation in proplasmepsins. Each inhibitor molecule is in contact with two molecules of HAP, interacting with the carboxylate group of the catalytic Asp215 of one HAP protomer through a water molecule, while also making a direct hydrogen bond to Glu278A' of the other protomer. A comparison of the shifts in the positions of the catalytic residues in the inhibitor complex presented here with those published previously gives further hints regarding the enzymatic mechanism of HAP.

Indexed as

AnimalsAspartic AcidAspartic Acid ProteasesCatalytic DomainCrystallizationCrystallography, X-RayEscherichia coliHistidineHumansMolecular ConformationPlasmodium falciparumProtein FoldingProtein Structure, TertiaryRecombinant Fusion ProteinsSwineAspartic AcidAspartic Acid ProteasesHistidineRecombinant Fusion Proteins

Identifiers

PMID21928835
PMCPMC3501826
OpenAlexW2029431187

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.